In this interview discover further details of the JAVELIN Merkel 200 that led to the approval of the first immunotherapy treatment indicated in the EU and the first US FDA-approved systemic therapy for merkel cell carcinoma.
Browsing: Disease Area > Skin
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center (NC, USA) are developing a potential new immunotherapy strategy for melanoma.
Results from two international clinical trials yield promising results for halting the mestatise of melanoma, yield novel treatment options for melanoma and may help stop this form of cancer metastizing.
In this interview from Melanoma Management find out about the use of teledermatology, how Guiseppe is developing more accurate methods for the early recognition of melanoma and his outlook for the future of this field.
Editor, Jade Parker recently spoke with David Adams, Wellcome Trust Sanger Institute (Cambridge, UK) about utilizing DNA sequencing of patients and genetic screens in human cells and mice to identify cancer genes and genetic interactions.
In this infographic gain a visual snapshot of a review article in which over 50 leaders in the dermatology field critically assess current screening practice for melanoma in an effort to propose rational, risk-based, data-driven guidelines for skin cancer screening.
In this editorial, we will review emerging evidence for the relationship between sexual orientation, indoor tanning and melanoma and discuss implications for clinical practice, research and public health.
This editorial discusses the impact of the numer of melanocytic nevi (moles) and the risk of developing melanoma.
This article provides a immunotherapy perspective of Ipilimumab, a CTLA-4-targeted monoclonal antibody, reviewing drug mechanism, blockade, combination therapies and future prospectives.
A group of researchers from the University of Missouri (MO, USA) report a novel technique for detecting and analyzing melanoma cells which could lead to better and faster diagnosis of the disease.